Paraneoplastic cerebellar degeneration and gynecologic malignancies

International Journal of Gynecological Cancer

Volumn 7, Issue 4, 1997, Pages 279-283

  Cardosi, R J ^a,b   Decesare, S L ^a   Roberts, W S ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Anti Yo antibodies; Gynecologic cancer; Paraneoplastic cerebellar degeneration

Indexed keywords

CELL ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BREAST CANCER; CASE REPORT; CEREBELLAR ATAXIA; CEREBELLUM ATROPHY; CEREBELLUM DEGENERATION; CEREBROSPINAL FLUID LEVEL; DISEASE ASSOCIATION; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT CANCER; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PURKINJE CELL;

EID: 0030724015     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1997.00454.x     Document Type: Article

References (29)

1. Brouwer B. Beitrag zue Kenntnis der chronischer diffusen Kir hirnerkrankungen. Neurol Centralbl 1919; 38: 674-82.
2. Parker HL, Kernohan JW. Parenchymatous cortical cerebellar atrophy (chronic atrophy of Purkinje's cells). Brain 1933; 56: 191-212.
3. McLellan R, Currie JL, Royal W, Rosenshein NB. Ovarian carcinoma and paraneoplastic cerebellar degeneration. Obstet Gynecol 1988; 72: 922-4.
4. Hall DJ, Dyer ML, Parker JC Jr. Ovarian cancer complicated by cerebellar degeneration: A paraneoplastic syndrome. Gynecol Oncol 1985; 21: 240-6.
5. Paone JF, Jeyasingham K. Remission of cerebellar dysfunction after pneumonectomy for bronchogenic carcinoma. N Engl J Med 1980; 302: 156.
6. Hetzel DJ, Stanhope CR, O'Neill BP, Lennon VA. Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-purkinje cell antibodies and limited in metastatic volume. Mayo Clin Proc 1990; 65: 1558-63.
7. Hammack JE, Kimmel DW, O'Neill BP, Lennon VA. Paraneoplastic cerebellar degeneration: A clinical comparison of patients with and without purkinje cell cytoplasmic antibodies. Mayo Clin Proc 1990; 65: 1423-31.
8. Bradley WG, Daroff RB, Fenichel GM, Marsden CD. Neurology in Clinical Practice: The Neurological Disorders, 2nd edn. Boston: Butterworth-Heinemann, 1996: 1166-7.
9. Swash M, Oxbury J. Clinical Neurology, 1st edn. New York: Churchill Livingstone, 1991: 1658-9.
10. Batson OA, Fantle DM, Stewart JA. Paraneoplastic encephalomyelitis: dramatic response to chemotherapy alone. Cancer 1992; 69: 1291-3.
11. Kearsley JH, Johnson P, Halmagyi GM. Paraneoplastic cerebellar disease; remission with excision of primary tumor. Arch Neurol 1985; 42: 1208-10.
12. Greenlee JE, Lipton HL. Anticerebellar antibodies in serum and cerebrospinal fluid of a patient with oat cell carcinoma of the lung and paraneoplastic cerebellar degeneration. Ann Neurol, 1986; 19: 82-5.
13. Moll JWB, Henzen-Logmans SC, Van Der Meche PGA, Vecht VHJ. Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 1993; 56: 112 (letter to the editor).
14. Trotter JL, Hendin BA, Osterland CK. Cerebellar degeneration with Hodgkin's disease: an immunological study. Arch Neurol 1976; 33: 660-1.
15. Dalmau J, Posner JB. Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. Neurology 1994; 44: 2241-6.
16. Lennon VA. Paraneoplastic autoantibodies: the case for a descriptive generic nomenclature. Neurology 1994; 44: 2236-40.
17. Graus F, Cordon-Cardo C, Posner JB. Neuronal antinuclear antibody in sensory neuropathy from lung cancer. Neurology 1985; 35: 538-43.
18. Budde-Steffen C, Anderson NE, Rosenblum MK, et al. An anti-neuronal autoantibody in paraneoplastic opsoclonus. Ann Neurol 1988; 23: 528-31.
19. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42: 1931-7.
20. Furneaux HM, Rosenblum MK, Dalmau J, Wong E, Woodruff P, Graus F, Posner JB. Selective expression of purkinje cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990; 322: 1844-51.
21. Greenlee JE, Brashear HR. Antibodies to cerebellar purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol 1983; 14: 609-13.
22. Cunningham J, Graus F, Anderson NE, Posner JB. Partial characterization of the purkinje cell antigens in paraneoplastic cerebellar degeneration, Neurology 1986; 36: 1164-8.
23. Brasher HR, Greenlee JE, Jaeckle KA, Rose JW. Anticerebellar antibodies in neurologically normal patients with ovarian neoplasms. Neurology 1989; 39: 1605-9.
24. Altermatt HJ, Rodriquez M, Scheithauer BW, Lennon VA. Paraneoplastic ant-purkinje and type I anti-neuronal nuclear autoantibodies bind selectively to central, peripheral, and autonomic nervous system cells. Lab Invest 1991; 65: 412-20.
25. Lennon VA, Sas DF, Busk MF, et al. Enteric neuronal autoantibodies in pseudoobstruction with small cell lung carcinoma. Gastroenterology 1991; 100: 137-42.
26. Graus F, Dalmau J. Enteric neuronal antibodies and pseudoobstruction. Gastroenterology 1991; 101: 1142-4.
27. Waterhouse DM, Natale RB, Cody RL. Breast cancer and paraneoplastic cerebellar degeneration. Cancer 1991; 68: 1835-41.
28. Ben David Y, Warner E, Levitan M, Sutton DMS, Malkin MG, Dalmau JO. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. Cancer 1996; 78: 2153-6.
29. Sliwa JA, Thatcher S, Jet J. Paraneoplastic subacute cerebellar degeneration: functional improvement and the role of rehabilitation. Arch Phys Med Rehabil 1994; 75: 355-357.